Novartis is buying dry-eye medicine brand ‘Xiidra’ from Takeda Pharmaceutical for up to $5.3 billion as the Swiss pharma-maker refreshes its ophthalmic medicines portfolio with a potential blockbuster. The deal calls for $3.4 billion up front and milestone payments up to $1.9 billion, Novartis said.
Swiss drugmaker Novartis on won US approval for its gene therapy Zolgensma for spinal muscular atrophy (SMA), the leading genetic cause of death in infants, and priced the one-time treatment at a record $2.125 million. The Food and Drug Administration approved Zolgensma for children
Novartis plans to answer a US senator who demanded details about data manipulation related to its gene therapy Zolgensma, amid scrutiny of the Swiss drugmaker’s decision to delay informing regulators
Eleven pharma companies led by Pfizer and Novartis have set aside a combined $2 billion to invest in gene therapy manufacturing sector since 2018, according to a Reuters analysis, in a drive to better control production of the world’s priciest medicines.